Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: A 6-month, double-blind trial

Journal of Clinical Psychopharmacology

Volumn 29, Issue 1, 2009, Pages 44-50

  Adler, Lenard A ^a,b   Spencer, Thomas ^c   Brown, Thomas E ^d   Holdnack, James ^e   Saylor, Keith ^f   Schuh, Kory ^g   Trzepacz, Paula T ^g,h,i,j   Williams, David W ^g   Kelsey, Douglas ^g  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Harcourt Assessment Inc   (United States)

^f NeuroScience Inc   (United States)

^g ELI LILLY AND COMPANY   (United States)

^h UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

ADHD; Adult; Atomxetine; Duration of effect; Once daily

Indexed keywords

ATOMOXETINE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ADHD INVESTIGATOR SYMPTOM RATING SCALE; ADULT; ADULT ADHD QUALITY OF LIFE SCALE; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONNER ADULT ADHD RATING SCALE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DREAM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; URINARY HESITANCY; XEROSTOMIA; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPYLAMINES; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 62649135353     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318192e4a0     Document Type: Article

References (27)

1. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD. An overview. Ann N Y Acad Sci. 2001;931:1-16.
2. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
3. Faraone SV. ADHD in adults - a familiar disease with unfamiliar challenges. CNS Spectr. 2007;12(suppl 23):14-17.
4. Dodson WW. Pharmacotherapy of adult ADHD. J Clin Psychol. 2005;61:589-606.
5. Wilens TE, Dodson W. A clinical perspective of attention-deficit/ hyperactivity disorder into adulthood. J Clin Psychiatry. 2004;65(10):1301-1313.
6. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112-120.
7. Adler L, Dietrich A, Reimherr FW, et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry. 2006;18(2):107-113.
8. Strattera. Strattera full prescribing information. Revision May 2007. Available at: http://www.Strattera.com. Accessed July 3, 2007.
9. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1-e8.
10. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):187-201.
11. Adler LA. Adult ADHD: current understanding. Psychopharmacology of adult disorders originating in childhood. Paper presented at: American Academy of Child and Adolescent Psychiatry 51st Annual Meeting, session Institute 7; October 2004; Washington, DC.
12. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: US Department of Health, Education and Welfare; 1976.
13. Adler LA, Spencer T, Faraone SV, et al. Training raters to assess adult ADHD: reliability of ratings. J Atten Disord. 2005;8(3):121-126.
14. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). North Tonawanda, NY: Multi-Health Systems; 1999.
15. Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245-256.
16. Brod M, Johnston J, Able S, et al. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res. 2006; 15(1):117-129.
17. Brod M, Perwien A, Adler L, et al. Conceptualization and assessment of quality of life for adults with attention-deficit/hyperactivity disorder. Prim Psychiatry. 2005;12(6):58-64.
18. SAS Institute. SAS/STAT Software: Changes and Enhancements Through Release 6.12. 4th ed. Cary, NC: SAS Institute; 1997.
19. Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatry. 2002;63(suppl 12):29-35.
20. Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord. 2008;12(3):248-253.
21. Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008;96(1-2):145-154.
22. Spencer T, Kratochvil C, Sangal RB, et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol. 2007;17(5):689-699.
23. Matza LS, Johnston JA, Faries DE, et al. Responsiveness of the adult attention-deficit/hyperactivity disorder quality of life scale (AAQoL). Qual Life Res. 2007;16(19):1511-1520.
24. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625-639.
25. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829-835.
26. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(5):456-463.
27. Adler LA, Faraone SV, Spencer TJ, et al. The reliability and validity of self and investigator ratings of ADHD in adults. J Atten Disord. 2008;11(6):711-719. Epub 2007 Nov. 19.